Developer docs
API playgroundTry for free, no card

Search company profiles

Ichnos Sciences

Full company profile

uuid0009hpv

Namestring
Ichnos Sciences
Legal namestring
IGI, Inc.
Company typeenum
Private
Founded yearint
2019
Descriptiontext

Ichnos Glenmark Innovation (IGI, Inc.), operating under the Ichnos Sciences brand, is a private clinical-stage biotechnology company developing innovative biologics for oncology. The company is a joint venture combining Glenmark's pharmaceutical infrastructure with Ichnos's biologics discovery capabilities, and is headquartered in New York with additional operations in Switzerland (process development, manufacturing, and a research center at Biopole, Lausanne) and India (R&D support hub in Mahape, Mumbai). IGI focuses on hematological malignancies and solid tumors, with stated patients as the end-user beneficiary.

The company's core technology is the proprietary BEAT® protein engineering platform, which enables development of full-length multispecific antibodies with an emphasis on flexibility and manufacturability. Its lead clinical asset is ISB 2001, a first-in-class trispecific antibody (CD38 x BCMA x CD3) in Phase 1b development for multiple myeloma, designed to overcome mechanisms of escape from existing treatments. The pipeline additionally includes ISB 2301, a preclinical next-generation multispecific immune cell activator that targets three tumor-associated antigens and engages both T cells and natural killer (NK) cells, plus earlier-stage candidates ISB 1442, ISB 1342, and GRC 54276. IGI employs approximately 100 people across its three innovation centers, with a management team reporting 120+ years of combined pharmaceutical and biotech experience and a Scientific Advisory Board with expertise in immuno-oncology and protein engineering.

As a clinical-stage company, IGI's revenue model is predicated on advancing pipeline candidates through clinical development toward regulatory approval, with future economics expected to flow from licensing, royalties, or partnership-based commercialization rather than current product sales. The company distributes information through its corporate website, scientific publications, medical conference presentations, and a LinkedIn presence, and has signaled openness to external collaboration through a dedicated partnerships channel. No funding rounds, revenue figures, or public institutional investors are disclosed in the source data.

Short descriptiontext

Ichnos Glenmark Innovation (IGI, Inc.) is a private clinical-stage biotechnology company developing first-in-class multispecific antibody therapies in oncology, powered by its proprietary BEAT® protein engineering platform, with a lead asset (ISB 2001) in Phase 1b for multiple myeloma and a preclinical solid-tumor candidate (ISB 2301).

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersNew York, United States
HQ citystring
New York
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
oncology biologics, multispecific antibodies, cancer therapeutics, biopharmaceutical research, clinical-stage biotechnology
Industry2 codes
PRIMARYHLAAAIAC
Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGABAC
Biologics (mAbs/Recombinant Proteins) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Oncology Biologics
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pipeline Development and Potential Commercialization
TypeLicensing Royalties
Description

As a clinical-stage biotechnology company, IGI is developing novel biologics in oncology. The revenue model is based on advancing pipeline candidates through clinical development toward potential regulatory approval and commercialization, with focus on hematological malignancies and solid tumors.

iginnovate.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Supply Chain, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Ichnos Sciences is a clinical-stage biotechnology company that develops innovative multispecific antibody therapeutics for the treatment of cancer. The company leverages its proprietary BEAT® technology platform to engineer biologics that engage multiple immune system targets, with a current pipeline of candidates targeting hematological malignancies and solid tumors at preclinical to Phase 1b stages of development.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

IGI, Inc. (Ichnos Glenmark Innovation) is a global, clinical-stage biotechnology company developing innovative biologics in oncology. The company operates with its proprietary BEAT® technology platform for developing multispecific antibodies. The core pipeline includes ISB 2001 (CD38 x BCMA x CD3 trispecific T cell engager in Phase 1b for multiple myeloma) and ISB 2301 (next-generation multispecific immune cell activator in preclinical stage targeting 3 tumor-associated antigens and activating both T cells and NK cells). Additional pipeline candidates include ISB 1442, ISB 1342, and GRC 54276. The company's Multispecifics™ portfolio targets hematological malignancies and solid tumors, aiming to deliver breakthrough curative therapies.

Product and service1 record
1ISB 2001
Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Ichnos Glenmark Innovation (IGI) is a joint venture/partnership between Ichnos and Glenmark, combining Glenmark's legacy and Ichnos's innovative biologics capabilities to develop breakthrough oncology therapies. The partnership leverages Glenmark's pharmaceutical expertise and infrastructure alongside Ichnos's proprietary BEAT® technology platform.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Zymeworks develops multispecific antibodies using its Azymetric and EFECT platforms for oncology indications, making it a direct competitor to IGI's BEAT® multispecific antibody platform. Both companies focus on engineering novel antibody formats to engage multiple targets simultaneously in cancer treatment.

TypeDirect peer
Description

Genmab is a leading developer of bispecific antibodies using its proprietary DuoBody platform, with approved products including teclistamab for multiple myeloma — directly competing with IGI's ISB 2001 in the same indication. Both companies engineer multispecific antibodies for hematologic and solid tumor oncology.

TypeDirect peer
Description

MacroGenics develops multispecific antibodies (DART and TRIDENT platforms) for cancer immunotherapy, with multiple clinical-stage oncology assets. Their T cell engager approach and protein engineering platform closely parallel IGI's BEAT® technology and multispecific strategy.

TypeDirect peer
Description

Xencor's XmAb protein engineering platform generates bispecific and multispecific antibodies with multiple clinical-stage oncology assets. Like IGI, Xencor focuses on engineering novel antibody formats to address oncology indications including hematologic malignancies.

TypeDirect peer
Description

Harpoon developed T cell engagers using its TriTAC and ProTriTAC platforms for multiple myeloma and solid tumors, with HPB-2001 (BCMA x CD3 x albumin) being a near-direct competitor to IGI's ISB 2001. Acquired by Merck in 2024, validating the strategic value of the T cell engager space IGI plays in.

TypeDirect peer
Description

Maverick developed conditional T cell engagers (COBRA platform) for solid tumors, with a similar multispecific approach to IGI's pipeline. Acquired by Takeda in 2021, representing another validation of the multispecific T cell engager space IGI operates in.

TypeBroad incumbent
Description

Regeneron is a major biopharmaceutical company with bispecific antibody capabilities (linvoseltamab for multiple myeloma, odronextamab) and a broader oncology and antibody portfolio. As a broad incumbent, it competes with IGI's multispecific approach while also offering partnership/licensing optionality.

TypeEmerging player
Description

AbCellera operates an antibody discovery and engineering platform partnering with multiple biotech and pharma companies to develop therapeutic antibodies. While not directly developing multispecific assets like IGI, it represents an alternative platform-based antibody discovery model in the same therapeutic space.

TypeEmerging player
Description

CytomX develops Probody therapeutics — conditionally activated antibodies designed to improve tumor selectivity. Their platform-based approach to engineering antibody specificity in oncology parallels IGI's BEAT® platform strategy of using protein engineering to overcome therapeutic limitations.

TypeBroad incumbent
Description

Roche has extensive bispecific antibody capabilities through its CrossMAb and other platforms, with approved products like glofitamab and mosunetuzumab. As a broad incumbent with deep oncology infrastructure, Roche is both a potential competitor and a likely partnership/licensing partner for clinical-stage multispecific antibody developers like IGI.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat2 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Ichnos Sciences

Oncology Biologicsichnossciences.com

Ichnos Glenmark Innovation (IGI, Inc.) is a private clinical-stage biotechnology company developing first-in-class multispecific antibody therapies in oncology, powered by its proprietary BEAT® protein engineering platform, with a lead asset (ISB 2001) in Phase 1b for multiple myeloma and a preclinical solid-tumor candidate (ISB 2301).

What Ichnos Sciences does

Ichnos Glenmark Innovation (IGI, Inc.), operating under the Ichnos Sciences brand, is a private clinical-stage biotechnology company developing innovative biologics for oncology. The company is a joint venture combining Glenmark's pharmaceutical infrastructure with Ichnos's biologics discovery capabilities, and is headquartered in New York with additional operations in Switzerland (process development, manufacturing, and a research center at Biopole, Lausanne) and India (R&D support hub in Mahape, Mumbai). IGI focuses on hematological malignancies and solid tumors, with stated patients as the end-user beneficiary.

The company's core technology is the proprietary BEAT® protein engineering platform, which enables development of full-length multispecific antibodies with an emphasis on flexibility and manufacturability. Its lead clinical asset is ISB 2001, a first-in-class trispecific antibody (CD38 x BCMA x CD3) in Phase 1b development for multiple myeloma, designed to overcome mechanisms of escape from existing treatments. The pipeline additionally includes ISB 2301, a preclinical next-generation multispecific immune cell activator that targets three tumor-associated antigens and engages both T cells and natural killer (NK) cells, plus earlier-stage candidates ISB 1442, ISB 1342, and GRC 54276. IGI employs approximately 100 people across its three innovation centers, with a management team reporting 120+ years of combined pharmaceutical and biotech experience and a Scientific Advisory Board with expertise in immuno-oncology and protein engineering.

As a clinical-stage company, IGI's revenue model is predicated on advancing pipeline candidates through clinical development toward regulatory approval, with future economics expected to flow from licensing, royalties, or partnership-based commercialization rather than current product sales. The company distributes information through its corporate website, scientific publications, medical conference presentations, and a LinkedIn presence, and has signaled openness to external collaboration through a dedicated partnerships channel. No funding rounds, revenue figures, or public institutional investors are disclosed in the source data.

Ichnos Sciences firmographics

Firmographics
Name
Ichnos Sciences
Legal name
IGI, Inc.
Website
https://ichnossciences.com
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
51–100 employees
Short description
Ichnos Glenmark Innovation (IGI, Inc.) is a private clinical-stage biotechnology company developing first-in-class multispecific antibody therapies in oncology, powered by its proprietary BEAT® protein engineering platform, with a lead asset (ISB 2001) in Phase 1b for multiple myeloma and a preclinical solid-tumor candidate (ISB 2301).
Ownership category
akta.pro rank

Ichnos Sciences industry classification

Industry
Product category
Oncology Biologics
NAICS
Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAIAC
Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGABAC
Biologics (mAbs/Recombinant Proteins) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)

Keywords

  • Oncology biologics
  • Multispecific antibodies
  • Cancer therapeutics
  • Biopharmaceutical research
  • Clinical-stage biotechnology

Where Ichnos Sciences is headquartered

Location

Headquarters

HQ city
New York
HQ country
United States
HQ region
North America

Offices4 records

Markets served

Ichnos Sciences business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Supply Chain, Others

Revenue model

  1. Pipeline Development and Potential Commercialization: As a clinical-stage biotechnology company, IGI is developing novel biologics in oncology. The revenue model is based on advancing pipeline candidates through clinical development toward potential regulatory approval and commercialization, with focus on hematological malignancies and solid tumors.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Ichnos Sciences product offering

Product offering

Core offering

Ichnos Sciences is a clinical-stage biotechnology company that develops innovative multispecific antibody therapeutics for the treatment of cancer. The company leverages its proprietary BEAT® technology platform to engineer biologics that engage multiple immune system targets, with a current pipeline of candidates targeting hematological malignancies and solid tumors at preclinical to Phase 1b stages of development.

Product overview

IGI, Inc. (Ichnos Glenmark Innovation) is a global, clinical-stage biotechnology company developing innovative biologics in oncology. The company operates with its proprietary BEAT® technology platform for developing multispecific antibodies. The core pipeline includes ISB 2001 (CD38 x BCMA x CD3 trispecific T cell engager in Phase 1b for multiple myeloma) and ISB 2301 (next-generation multispecific immune cell activator in preclinical stage targeting 3 tumor-associated antigens and activating both T cells and NK cells). Additional pipeline candidates include ISB 1442, ISB 1342, and GRC 54276. The company's Multispecifics™ portfolio targets hematological malignancies and solid tumors, aiming to deliver breakthrough curative therapies.

Differentiator

Problem solved

Functional benefit

Products and services

  • ISB 2001

Companies that use Ichnos Sciences

Customer profile

Named customers1 record

Segments2 records

Ideal customer profiles1 record

Ichnos Sciences technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

Ichnos Sciences partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • GlenmarkcoreStrategic or Co-development PartnerIchnos Glenmark Innovation (IGI) is a joint venture/partnership between Ichnos and Glenmark, combining Glenmark's legacy and Ichnos's innovative biologics capabilities to develop breakthrough oncology therapies. The partnership leverages Glenmark's pharmaceutical expertise and infrastructure alongside Ichnos's proprietary BEAT® technology platform.

Scale indicators3 records

Recent moves6 records

Expansion highlights4 records

Ichnos Sciences competitors and assessment

Company assessment

Direct peers

  • Zymeworks: Zymeworks develops multispecific antibodies using its Azymetric and EFECT platforms for oncology indications, making it a direct competitor to IGI's BEAT® multispecific antibody platform. Both companies focus on engineering novel antibody formats to engage multiple targets simultaneously in cancer treatment.
  • Genmab: Genmab is a leading developer of bispecific antibodies using its proprietary DuoBody platform, with approved products including teclistamab for multiple myeloma — directly competing with IGI's ISB 2001 in the same indication. Both companies engineer multispecific antibodies for hematologic and solid tumor oncology.
  • MacroGenics: MacroGenics develops multispecific antibodies (DART and TRIDENT platforms) for cancer immunotherapy, with multiple clinical-stage oncology assets. Their T cell engager approach and protein engineering platform closely parallel IGI's BEAT® technology and multispecific strategy.
  • Xencor: Xencor's XmAb protein engineering platform generates bispecific and multispecific antibodies with multiple clinical-stage oncology assets. Like IGI, Xencor focuses on engineering novel antibody formats to address oncology indications including hematologic malignancies.
  • Harpoon Therapeutics (acquired by Merck): Harpoon developed T cell engagers using its TriTAC and ProTriTAC platforms for multiple myeloma and solid tumors, with HPB-2001 (BCMA x CD3 x albumin) being a near-direct competitor to IGI's ISB 2001. Acquired by Merck in 2024, validating the strategic value of the T cell engager space IGI plays in.
  • Maverick Therapeutics (acquired by Takeda): Maverick developed conditional T cell engagers (COBRA platform) for solid tumors, with a similar multispecific approach to IGI's pipeline. Acquired by Takeda in 2021, representing another validation of the multispecific T cell engager space IGI operates in.

Broad incumbents

  • Regeneron: Regeneron is a major biopharmaceutical company with bispecific antibody capabilities (linvoseltamab for multiple myeloma, odronextamab) and a broader oncology and antibody portfolio. As a broad incumbent, it competes with IGI's multispecific approach while also offering partnership/licensing optionality.
  • Roche: Roche has extensive bispecific antibody capabilities through its CrossMAb and other platforms, with approved products like glofitamab and mosunetuzumab. As a broad incumbent with deep oncology infrastructure, Roche is both a potential competitor and a likely partnership/licensing partner for clinical-stage multispecific antibody developers like IGI.

Emerging players

  • AbCellera Biologics: AbCellera operates an antibody discovery and engineering platform partnering with multiple biotech and pharma companies to develop therapeutic antibodies. While not directly developing multispecific assets like IGI, it represents an alternative platform-based antibody discovery model in the same therapeutic space.
  • CytomX Therapeutics: CytomX develops Probody therapeutics — conditionally activated antibodies designed to improve tumor selectivity. Their platform-based approach to engineering antibody specificity in oncology parallels IGI's BEAT® platform strategy of using protein engineering to overcome therapeutic limitations.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat2 records

Key risks6 records

Key highlights6 records

Customer concentration

Ichnos Sciences social profiles

Digital presence

Ichnos Sciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Ichnos Sciences leadership team

Management profile

Number of profiles

Profiles6 records

Ichnos Sciences funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Ichnos Sciences M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ichnos Sciences

What does Ichnos Sciences do?

Ichnos Sciences is a clinical-stage biotechnology company that develops innovative multispecific antibody therapeutics for the treatment of cancer. The company leverages its proprietary BEAT® technology platform to engineer biologics that engage multiple immune system targets, with a current pipeline of candidates targeting hematological malignancies and solid tumors at preclinical to Phase 1b stages of development.

Is Ichnos Sciences a public or private company?

Ichnos Sciences is a private company. It is classified as corporate owned and is currently operating.

When was Ichnos Sciences founded?

Ichnos Sciences was founded in 2019. It employs 51 to 100 people.

Where is Ichnos Sciences based?

Ichnos Sciences is headquartered in New York, United States, in the North America region.

How does Ichnos Sciences make money?

One revenue line is on record: pipeline Development and Potential Commercialization.

Who are Ichnos Sciences's main competitors?

Direct peers on record are Zymeworks, Genmab, MacroGenics, Xencor, Harpoon Therapeutics (acquired by Merck) and Maverick Therapeutics (acquired by Takeda). Broad incumbents are Regeneron and Roche. Emerging players are AbCellera Biologics and CytomX Therapeutics.

Does Ichnos Sciences have an API?

No public API is recorded for Ichnos Sciences.

What industry is Ichnos Sciences in?

Ichnos Sciences's product category is Oncology Biologics. Its primary akta.pro industry code is HLAAAIAC, Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization), with a secondary code of HLAGABAC, Biologics (mAbs/Recombinant Proteins) CDMO. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireICHNOS SCIENCES ANNOUNCES INITIATION OF FIRST-IN-HUMAN CLINICAL TRIAL FOR ISB 2001Ichnos Sciences has dosed the first patient in a Phase 1 first-in-human clinical trial of ISB 2001, a BCMA x CD38 x CD3 trispecific antibody for relapsed or refractory multiple myeloma. The trial will enroll approximately 80 participants across multiple centers in the U.S. and Australia, following IND clearance from the FDA and approval from Australia's Human Research Ethics Committee. This milestone marks Ichnos' first T-cell engaging trispecific antibody based on its proprietary BEAT® platform and represents the company's third clinical-stage oncology asset to receive orphan drug designation.PR NewswireICHNOS SCIENCES ENTERS LICENSING AGREEMENT FOR OX40 ANTAGONIST MONOCLONAL ANTIBODY PORTFOLIO WITH ASTRIA THERAPEUTICSIchnos Sciences, a global clinical-stage biotechnology company, has entered into an exclusive worldwide licensing agreement with Astria Therapeutics for its OX40 antagonist monoclonal antibody portfolio, including Telazorlimab and follow-on molecules. Under the terms, Astria will assume full responsibility for global development and commercialization, receiving up to $320 million in upfront, development, regulatory, and sales milestone payments, plus low double-digit royalties. The deal allows Ichnos to prioritize its oncology pipeline of multispecific antibodies while enabling Astria to advance an affinity-matured version of Telazorlimab with YTE half-life extension technology for atopic dermatitis.PR NewswireICHNOS SCIENCES RECEIVES ORPHAN DRUG DESIGNATION FOR FIRST-IN-CLASS BISPECIFIC (CD38 x CD47) ANTIBODY INNATE CELL MODULATOR, ISB 1442Ichnos Sciences Inc. announced that the U.S. Food and Drug Administration has granted orphan drug designation (ODD) to ISB 1442, a first-in-class biparatopic bispecific antibody targeting CD38 and CD47, for the treatment of relapsed/refractory multiple myeloma. ISB 1442 is the company's second clinical-stage asset to receive ODD for multiple myeloma and is currently being evaluated in a first-in-human Phase 1 study that began dosing patients in Australia in September 2022, with U.S. sites expected to open in Q2 2023. The designation qualifies Ichnos for incentives including tax credits, user fee waivers, and seven years of market exclusivity upon approval.PR NewswireICHNOS SCIENCES PRESENTS DATA SUPPORTING THREE ONCOLOGY ASSETS AT ASH 2022 ANNUAL MEETINGIchnos Sciences Inc. presented preclinical and clinical data on three oncology assets at the 64th American Society of Hematology Annual Meeting in December 2022, supporting the advancement of its first-in-class TREAT™ trispecific antibody ISB 2001 to a first-in-human clinical trial. The company announced plans to file IND and CTN applications during the first quarter of 2023 for a Phase 1 study in relapsed/refractory multiple myeloma. Data showed that ISB 2001 demonstrated superior tumor cell killing potency compared to other treatment options including teclistamab, alnuctamab, and EM-801 in ex vivo cytotoxicity assays.PR NewswireICHNOS SCIENCES DATA SELECTED FOR PRESENTATION AT THE 64TH ASH ANNUAL MEETINGIchnos Sciences Inc. announced that four abstracts presenting data on three oncology assets have been selected for the 64th American Society of Hematology Annual Meeting in December 2022. The assets include ISB 1342, ISB 1442, and ISB 2001, two of which are currently in Phase 1 clinical studies for relapsed/refractory multiple myeloma. The company highlighted its proprietary BEAT® platform technology and its mission to develop transformative, disease-centric cancer therapies.PR NewswireICHNOS SCIENCES FERA UNE PRÉSENTATION LORS DE LA CONFÉRENCE JEFFERIES HEALTHCARE EN 2022Ichnos Sciences Inc, a clinical-stage global biotechnology company, announced that its CEO, Cyril Konto, will present at the Jefferies Healthcare 2022 conference in New York on June 8, 2022. The presentation follows the company's recent selection of ISB 2001 TREAT1, its first BCMA and CD38-targeting trispecific T-cell engager antibody for multiple myeloma, as its next clinical development candidate, alongside two other pipeline programs — ISB 1342 and ISB 1442 — both in Phase 1 studies. The company stated its mission is to advance transformative therapies that extend and improve patients' lives through its proprietary BEAT® technology platform.PR NewswireICHNOS SCIENCES PRÄSENTIERT AUF DER JEFFERIES HEALTHCARE CONFERENCE 2022Ichnos Sciences Inc., a New York-based clinical-stage biotechnology company developing multispecific antibodies for oncology, announced that its President and CEO, Dr. Cyril Konto, will present at the Jefferies Healthcare Conference 2022 in New York on June 8, 2022. The announcement comes weeks after the company disclosed selection of its trispecific antibody ISB 2001 TREAT1 as the next clinical development candidate targeting BCMA and CD38 on multiple myeloma cells. Ichnos Sciences' pipeline also includes ISB 1342, a bispecific CD38 x CD3 antibody currently enrolling patients in a Phase 1 dose-escalation study, and ISB 1442, a biparatopic CD38 x CD47 antibody for which a Phase 1 study is expected to begin shortly.PR NewswireICHNOS SCIENCES TO PRESENT AT THE 2022 JEFFERIES HEALTHCARE CONFERENCEIchnos Sciences Inc., a clinical-stage biotechnology company focused on oncology, announced that its CEO Dr. Cyril Konto will present at the 2022 Jefferies Healthcare Conference in New York on June 8, 2022. The presentation will cover the company's pipeline of multispecific antibody candidates including ISB 2001, ISB 1342, and ISB 1442 for treating multiple myeloma. A live webcast of the presentation will be available for one year following the conference.PR NewswireICHNOS SCIENCES ANNOUNCES SELECTION OF TRISPECIFIC ANTIBODY ISB 2001 AS NEXT CLINICAL CANDIDATE FOR RELAPSED/REFRACTORY MULTIPLE MYELOMAIchnos Sciences Inc. announced the selection of ISB 2001, its first TREAT trispecific antibody targeting BCMA x CD38 x CD3, as its next clinical candidate for relapsed/refractory multiple myeloma, with IND-enabling studies now initiated. In vitro and in vivo studies demonstrated superior tumor-killing potency compared to currently approved multiple myeloma treatments. The company aims to advance ISB 2001 to a first-in-human study pending health authority clearance in 2023.